Year: 2025

SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate the study.Following the positive SAD/MAD data results announced in September for SCY-247, its second-generation fungerp, the Company expects to initiate a Phase 1 study with the IV formulation and a Phase 2 study for the treatment of invasive candidiasis. The Company aims to release clinical proof of concept data in invasive candidiasis in 2026 and is exploring non-dilutive funding opportunities to support the development of SCY-247.GSK remains committed to the relaunch of BREXAFEMME® with activities ongoing to transfer the NDA before the end of the year. Following the relaunch, SCYNEXIS stands to...

Declares Dividend of $0.15 per share for Q3 2025Represents Genco’s 25th Consecutive Quarterly Dividend NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today reported its financial results for the three months and nine months ended September 30, 2025. Third Quarter 2025 and Year-to-Date HighlightsDividendDeclared a $0.15 per share dividend for Q3 2025 25th consecutive quarterly dividendCumulative dividends of $7.065 per share or approximately 43% of our current share price1Q3 2025 dividend is payable on or about November 24, 2025 to all shareholders of record as of November 17, 2025GrowthAcquired the Genco Courageous, a high specification 2020-built...

— Lung cancer programs progressing with interim data updates expected in Q4 2025 — — Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 — — Cash, cash equivalents, short-term investments and restricted cash of $21.0 million as of September 30, 2025 — WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2025 and provided general business updates. “In the third quarter, we continued to progress Olvi-Vec’s development across multiple solid tumor indications, positioning the program for meaningful clinical milestones and key catalysts in the coming year in indications that, together, represent a multi-billion-dollar...

GAAP Net Income of $163 million, or $1.10 per diluted shareAdjusted Operating Income of $166 million, or $1.12 per diluted shareReturn on Equity of 12.4% and Adjusted Operating Return on Equity of 12.6%Primary Insurance in-force of $272 billion, a 2% year-over-year increasePMIERs Sufficiency of 162% or approximately $1.9 billionBook Value Per Share of $36.53 and Book Value Per Share excluding AOCI of $36.82Increased Full-Year Capital Return Guidance to approximately $500 million RALEIGH, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) — Enact Holdings, Inc. (Nasdaq: ACT) today announced financial results for the third quarter of 2025. “Enact continues to execute with discipline and purpose,” stated Rohit Gupta, President and CEO of Enact. “We delivered another strong quarter, maintained our prudent approach to risk management...

Reaffirms 2025 adjusted earnings guidance in the range of $4.00 to $4.20 per share, excluding merger-related costs, same as prior GAAP guidance Completed planned equity and debt financing activities for 2025 Filed settlement agreement for new customer rates at Nebraska natural gas utility Completing construction of Ready Wyoming 260-mile transmission expansion project to be in service by year-end Commenced construction of Lange II 99 MW generation facility in South Dakota to be in service during second half of 2026 Announced tax-free, all-stock merger with NorthWestern Energy in August and filed joint applications for regulatory approval in Montana, Nebraska and South Dakota in OctoberRAPID CITY, S.D., Nov. 05, 2025 (GLOBE NEWSWIRE) — Black Hills Corp. (NYSE: BKH) today announced financial results for the third quarter ended...

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — APA Corporation (Nasdaq: APA) today announced third-quarter 2025 results. Results can be found on the company’s website by visiting www.apacorp.com or investor.apacorp.com. APA will host a conference call on Nov. 6 at 10 a.m. Central time via the webcast link available on the company website to discuss the results. Following the conference call, a replay will be available for one year on the “Investors” page of the company’s website. About APA APA Corporation owns consolidated subsidiaries that explore for and produce oil and natural gas in the United States, Egypt and the United Kingdom and that explore for oil and natural gas offshore Suriname and elsewhere. APA posts announcements, operational updates, investor information and press releases on its website, www.apacorp.com. Contacts Investor:...

Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September 30, 2025 PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today provided a clinical update and reported its financial results for the third quarter ended September 30, 2025. “We believe the early clinical data for CTIM-76 provides encouraging early signs of antitumor activity for Context’s T cell engagers (“TCE”) in solid tumors where many other approaches have failed due to material safety issues or lack of efficacy,”...

Dallas, Texas, Nov. 05, 2025 (GLOBE NEWSWIRE) — CompX International Inc. (NYSE American: CIX) announced today net sales of $40.0 million for the third quarter of 2025 compared to $33.6 million in the same period of 2024. Operating income was $4.8 million in the third quarter of 2025 compared to $3.3 million in the same period of 2024. Net income was $4.2 million, or $.34 per basic and diluted common share, for the third quarter of 2025 compared to $3.5 million, or $.28 per basic and diluted common share, in the same period of 2024. For the nine months ended September 30, 2025, net sales were $120.6 million compared to $107.5 million in the previous year. Operating income was $17.0 million for the first nine months of 2025 compared to $12.1 million for the same period in 2024. Net income for the nine months ended September 30,...